Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted Therapy

29 Jan 2022

Abstract excerpt

Lung cancer is the most common cause of cancer-related deaths in both men and women, accounting for one-quarter of total cancer-related mortality globally. Lung adenocarcinoma is the major subtype of non-small cell lung cancer (NSCLC) and accounts for around 40% of lung cancer cases. Lung adenocarcinoma is a highly heterogeneous disease and patients often display variable histopathological morphology, genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer-related Molecular Pathways
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35158979
DOI: 10.3390/cancers14030708

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted TherapyPMID 35158979Read ↗

Genomic Alterations in the RB Pathway Indicate Prognostic Outcomes of Early-Stage Lung Adenocarcinoma.Semantic proximity Read ↗

Molecular charcterization of lung adenocarcinoma combining whole exome sequencing, copy number analysis and gene expression profilingSemantic proximity Read ↗

Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinomaSemantic proximity Read ↗

Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.Semantic proximity Read ↗

Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.Semantic proximity Read ↗

High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities.Semantic proximity Read ↗

Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung AdenocarcinomaSemantic proximity Read ↗

Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research networkSemantic proximity Read ↗

Genomic and immune profiling of pre-invasive lung adenocarcinoma.Semantic proximity Read ↗

The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.Semantic proximity Read ↗

Comprehensive molecular profiling of lung adenocarcinoma.Semantic proximity Read ↗

Integrated Analysis of Genomic and Immunological Features in Lung Adenocarcinoma With Micropapillary ComponentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.